Studies on etiology and pathogenesis of multiple sclerosis by HASH(0x7fe9443a6e88)
Studies on etiology and pathogenesis of multiple sclerosis 
PhD thesis 
Cecilia Raj da MD 
Department of Neurology, Albert Szent-Györgyi Medical and Pharmaceutical Center, 
University of Szeged, Szeged, Hungary 
and 
Department of Psychiatry and Neurochemistry, Institute of Clinical Neuroscience, 
Göteborg University, Sahlgrenska University Hospital Mölndal, Sweden 
2004 

Abstract 
An initial study in this thesis concerned the epidemiology of multiple sclerosis (MS) to 
provide a background for future clinical studies of MS patients. The cerebrospinal fluid 
bank was up-dated for similar reasons. Our epidemiological results were comparable to 
those found in the literature. The etiology of MS is still unknown. Environmental as well 
as genetic factors seem to be involved. Latent neurotrop human herpes virus 6 type A was 
more often detected in the CSF of MS patients suggesting an involvement in the 
initialization or progression of the disease. Genetic susceptibility of MS is presumed, but 
the genes involved have not been identified thus broad population based studies are needed 
to find the regions of interest. In an international survey 33 potential markers were found in 
the Hungarian population. Reporting rare cases of familial aggregation could provide 
additional data to the genetic susceptibility. We reported on three affected sisters and their 
healthy parents and grandparents. As evidence is piling up, that nervous and the immune 
system communicate using the sympathetic nervous system and the hypothalamo-pituitary-
adrenal gland axis as integrative interfaces, catecholamines and their role as a transmitter 
in both systems become more interesting in autoimmune diseases, such as MS. We found 
decreased norepinephrine levels in stable MS patients, while first-attack MS patients had 
higher epinephrine levels, suggesting an active immune system in those patients. In an 
open-labeled trial on long-term interferon-beta administration, sustained decrease in 
relapse rate were found, and in line with this finding, the days of hospitalization and 
steroid need during the year was also decreased. 
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1. Introduction 
1.1 Historical notes on MS 
One of the first recorded clinical case of MS originates from Auguste d'Este, Grandson of 
George III of England (1794-1848), but other cases are also cited, as the case of St. 
Lidwine of Schiedam and an Icelandic Viking woman named "Halla" from the 14th 
century. Other diaries from the 1800s and 1900s are that of the poet Heinrich Heine and 
Barbellion (as reviewed by Butler and Bennett) (1). The first pathoanatomical description 
originates from Robert Carswell (1838) and Jean Cruvelhier from 1842. The exact 
description of the clinical symptoms and histological signs of MS are from Jean Martin 
Charcot (1825-1893) and M. Vulpian described in the year 1868 (2), followed by the work 
of other prominent neurologists, as e.g. Babinski, who wrote his thesis on MS (3). 
1.2 Nomenclature 
MS is also known as disseminated sclerosis in the historical literature. It belongs to the 
group leukoencephalitis. This name points to the disorder mainly affecting the white 
matter. Other diseases from this group are: neuromyelitis optica (Devic's disease), which is 
considered to be the extreme form of MS, encephalomyelitis disseminata, parainfectious, 
postvaccinatious encephalomyelitis, Schilder's encephalitis periaxialis diffusa and Bald's 
sclerosis concéntrica (4). In 1996, a uniform nomenclature was introduced for the clinical 
course of this disease. These clinical forms are: benign, relapsing-remitting (RR), 
secondary progressive (SP), relapsing-progressive, primary progressive (PP) (5). 
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1.3 Epidemiology 
MS is the most common neurological disorder in young adults; the age of onset is usually 
between 20-40 years. The female:male ratio is 2:1, depending on the age of the onset. A 
distinction between low, medium and high-risk factor areas can be made on the basis of 
geographical lines of latitude. The disease is most, prevalent in high northern latitudes 
However, the new prevalence tests reveal that in both low and medium-risk factor areas 
there can in fact be an enhanced occurrence (6-8). In research on the etiologic factors of 
MS, the occurrence and clinical forms of the disease have been examined in different 
population groups, such as Mestizos, Indians, etc. (6, 9). The Gypsy minority race, just like 
the Lapps of Scandinavia, the North American Indians of Canada, the Afro-Americans, 
and the Maoris of New Zealand, have been found to be resistant against multiple sclerosis 
(10-15). In Hungary, Pálffy et al. (10) calculated the prevalence in Baranya County in 
1983, which was 37/100,000. The prevalence in Fejér County in Hungary in 1992 was 
found by Guseo et al. (16) to be 69/100,000. Unfortunately, some of those patients did not 
undergo MRI examinations. Dean (17) determined the prevalence of multiple sclerosis 
within the continental zone as 30-80/100,000. The occurrence was found to be related to 
geographical distribution, migration and genetic contribution (6,18-23). 
1.4 Etiology and pathogenesis 
Multiple sclerosis is an autoimmune demyelinating disease, where inflammation and 
axonal loss takes place at the same time (24, 25). The disease is characterized by 
inflammatory lesions in the white matter of the nervous system, consisting of a specific 
immune response to the myelin sheet. In MS, axonal loss is present in the pathogenesis of 
the disease at early stages (26, 27). Current hypotheses on the pathogenesis of MS suggest 
that the primary peripheral activation of autoreactive T helper-1 lymphocytes precede the 
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recognition of central nervous system (CNS) auto-antigens. These T cells proliferate, 
secrete cytokines and cross the blood brain barrier (BBB) to find their antigens in the CNS 
where they cause further inflammatory damage. It has been hypothesized that RR MS is 
driven by a systemic antigen presentation and that chronic progressive MS depends on the 
CNS presentation of antigens (28). Recent reports of studies point to an 
immunopathogenetic heterogeneity, where the patterns of demyelination were 
heterogeneous between patients, but homogenous within the plaques from the same patient 
(29). Four patterns of demyelination in MS were found: Pattern I is the macrophage 
associated demyelination, Pattern II is characterized by antibody mediated demyelination, 
mechanism responsible for Pattern III results in distal oligodendropathy and Pattern IV is 
primary oligodendrocyte degeneration. Pattern I closely resembles myelin destruction in 
mouse models of EAE. All patients with Devic's type neuromyelitis optica had Pattern II, 
Pattern III is commonly found in virus-induced human white-matter diseases and Balo's 
type concentric lesions, while Pattern IV have been found in a small subset of PP MS 
patients (as reviewed by Lassmann) (30). 
The etiology of MS is still not clear. Environmental, as well as genetic factors seem to be 
implicated in the pathogenesis of the disease. 
1.4.1. Environmentalfactors - Infectious theories 
The hypotheses of infectious involvement are based on the seasonal variation in the 
incidence of new MS cases, the geographic association of disease susceptibility with 
evidence of MS clustering, and the idea that anti-myelin T cells or autoantibodies could be 
elicited by molecular mimicry (as reviewed by Swanborg et al.) (31). Viral theories are 
based on epidemiological evidence of childhood exposure to infectious agents, the increase 
in disease exacerbations with viral infection, evidence that migration to and from high-risk 
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areas influences the likelihood of developing MS, abnormal immune responses to a variety 
of viruses, and the analogy with animal models and other human diseases in which viruses 
can cause diseases with long incubation periods, a RR course, and demyelination (as 
reviewed by Soldan et al.) (32). Many of these studies involve the demonstration of 
increased antibody titers to a particular virus, whereas some describe isolation of virus 
from MS material. However, no virus to date has been definitively associated with this 
disease. Human herpesvirus type 6 (HHV-6) is a P-herpes virus isolated initially from 
peripheral blood mononuclear cells of infected AIDS patients (32). There is both 
serological and molecular evidence that, HHV-6 might have a role in the pathogenesis of 
multiple sclerosis (MS). Isolates of HHV-6 are grouped as variants A and B, and the 
contradictory results using different serological and molecular assays (32, 33) raises the 
possibility that HHV-6A and HHV-6B might exert different effects in disease progression. 
Recent reports indicate that the two variants have distinct biological properties and 
pathogenic potentials. In an individual no cross-immunity exists between HHV-6A and 
HHV-6B despite their genomic similarity (34). In spite of the integrity of the BBB against 
HHV-7 (35), both HHV-6A (34) and HHV-6B (36) may reach the central nervous system 
(CNS). In children and adults with dual infection, only HHV-6A persisted in CSF, which 
suggested that HHV-6A had greater neurotropism, but HHV-6B tended to be more 
prominent in other tissues (34, 37). In contrast, the presence of HHV-6B sequences was 
found to be common in the brains from MS patients and controls, but the high degree 
expression of HHV-6B in the plaque-associated oligodendrocytes (to be destructed) 
suggests that rather local instead of general effects of viruses contribute to MS 
pathogenesis (36). 
v ' 
5 
1.4.2. Genetic factors 
One of the underlying cause of autoimmune diseases is the inheritance of sets of genetic 
components that individually form part of a functioning immune system but that, when 
combined, increase the chances of susceptibility to an autoimmune disorder (38). As 
results of modern genetic studies it became evident, that MS results from an interaction of 
genetic and nongenetic factors. Familial aggregation of MS is due to the genetic material 
these relatives share with the individual having MS, the disease appears to be oligogenic. 
HLA is not the deterministic gene, and genetic susceptibility factors may overlap, at least 
to some extent, among the general population and individuals having MS (19). Age 
adjusted family risks for MS were greater than the lifetime prevalence for the general 
population (39). Study of adopted and adoptive parents indicated that the excess of MS 
among relatives is dependent upon the sharing of genetic material (40). These findings 
were followed by molecular genetic studies for candidate genes. The only consistently 
positive finding has been for the major histocompatibility complex (MHC) located on 
chromosome 6p21 (as reviewed by Sadovnick) (19). 
1.5. Neuroimmunological interaction 
1.5.1. Interaction between the nervous and immune system 
During the immune response the CNS and the immune system communicate using the 
sympathetic nervous system and the HPA axis as integrative interfaces (41). 
Norepinephrine fulfills the criteria for a neurotransmitter in the lymphoid organs, which 
are receiving an extensive sympathetic innervation, and the target immune cells express 
adrenoreceptors. Through stimulation of these receptors, locally released or circulating 
catecholamines affect lymphocyte traffic and proliferation. Norepinephrine and 
epinephrine inhibit the Thl (pro-inflammatory) type cytokine production and stimulate the 
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Th2 (anti-inflammatory) type cytokine production (as reviewed by Elenkov et al. 2000 and 
Sanders and Straub, 2002) (41,42). 
1.5.2. Beta-adrenergic receptors 
The effect of catecholamines, secreted by the sympathetic nervous system, predominantly 
acts on human T cells of the CD8+, CD28" (suppressor) subset (43). This subset also has 
the highest p-adrenergic receptor density. Antigen presenting cells in the CNS and 
lymphocytes bear primarily P-adrenergic receptors. The lymphocytes of relapsing-
remitting MS patients (44), SP patients (43) and PP MS patients (45) express more P-
adrenergic receptors. Both EAE and human studies points to altered p-adrenerg receptor 
function in MS. Beta-adrenoreceptor agonists has been reported to suppress EAE 
symptoms (46, 47), while normal appearing white matter and plaques in MS patients are 
lacking p2-adrenerg receptors, which were present in the white matter of control brain (48, 
49). Catecholamines also affect NK cell function through P-adrenergic receptors (50). 
1.5.3. Catecholamines in MS 
Lymphocytes are actively involved in the synthesis, uptake and degradation of 
catecholamines (51, 52). Furthermore, catecholamines have been found inside the nuclear 
envelope (51), suggesting a possible direct interaction with the transcription machinery or 
via an interaction with the N F - K B regulatory system (53). Recent results suggest a crucial 
role of N F - K B 1 in the activation and differentiation of autoreactive T cells. Blocking N F -
KB function can be an effective way to prevent autoimmune encephalomyelitis (54). 
Elevated regional levels of catecholamines might lead to suppression and finally apoptosis 
that could partly explain the immune privilege of the brain (55). Sophisticated analytical 
methods made possible to measure the amount of catecholamines in a single lymphocyte in 
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the CNS (56) in a picomole level (10~12 mol/cell) (51). Polymorphisms of the gene 
encoding the terminal enzyme of the catecholaminergic biosynthesis pathway 
(phenylethanolamine N-methyltransferase) shows association with MS (57). 
1.6. Clinical features of MS 
As the name of the disease indicates, the clinical symptoms are also multiple: disturbances 
in the visual, motor, sensory and cognitive function. In 2001, an international panel revised 
the Poser's diagnostic criteria (58), the new criteria is known as McDonald's diagnostic 
criteria (59), which integrated the magnetic resonance imaging (MRI) with clinical and 
other paraclinical diagnostic methods, and defined the criteria of the clinically isolated 
syndromes and primary progressive form more precisely. The focus still remained on the 
objective demonstration of dissemination of lesions in both time and space. 
1.7. Magnetic resonance imaging (MRI) 
With the help of the more sophisticated diagnostic tests (e.g. MRI) the diagnosis of MS 
became easier. The hallmark of MS on MR images are the T2 weighted lesions, on T1 
scans the black holes and the Gadolinium enhancement in active lesions, brain atrophy has 
been detected at early stages (as reviewed by Miller et al., 1998) (60). 
1.8. CSF findings 
Cell count in MS is usually normal, or slightly elevated, pleiocytosis is also reported. The 
CSF cytology has not a typical appearance. In the active phase activated lymphocytes can 
be found. The CSF protein concentrations are often increased, and the blood-CSF barrier is 
many times damaged. Elevated albumin ratio, total protein, gamma globulin level and 
pathological IgG index is often found (61, 62). A relation between age and protein levels in 
the CSF was found in healthy individuals (63). The gammaglobulins in the CSF migrate in 
agarose electrophoresis as abnormal discrete populations, the oligoclonal bands (OCB) 
(64). These bands were seen in 95% of the patients with isoelectric focusing (65). 
Quantitative measurements of IgG production in the CNS are less sensitive in the diagnosis 
of MS, than isoelectric focusing. 
1.9. The interferonP treatment in MS 
Beta-IFNs are used to treat clinically active MS patients to reduce the relapse rate and 
decrease the progression of the disease (66, 67). In the mechanism of action 
immunomodulatory rather than antiviral or antiproliferative effects seem to be operative. 
Beta-IFNs down regulate the IFN-gamma induced increase in MHC class-H molecules on 
peripheral blood monocytes and other antigen presenting cells, inhibits monocyte 
activation and antigen presentation to T cells (see recent review by Milo and Panitch) (68). 
Beta-IFN inhibits IFN-gamma, TNF-a and lymphotoxin secretion, up-regulation of the 
anti-inflammatory cytokines TGFp and IL-10, and suppression of IL-12. These effects all 
contribute to a shift from Thl to Th2 cell-mediated immune responses. It prevents 
disruption of the BBB and the migration of lymphocytes into the CNS, as evidenced by the 
dramatic decline in the number of enhancing MRI lesions in patients with MS who where 
treated with IFNp-lb or -la. Beta-IFN quickly binds to its receptor on target cells and 
activates interferon-inducible genes that mediate various activities. Some of these gene 
products, e.g. 2,5-oligoadenylate synthetase, p2-microglobulin and neopterin, serve as 
biological markers. After single sc. dose of IFNP-lb, their levels are elevated for more 
than 3 days. The most often occurring side effects of the P-IFN therapy are flu-like 
symptoms and depression (68). Despite the clinical advances, the mechanisms by which P-
IFN works in MS remain unclear. 
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Other medications used in MS e.g. glatiramer acetate, intravenous IgG, mitoxantron are not 
discussed in detail in this thesis. 
1.10. Aims of the study 
To calculate the prevalence and incidence of MS in the population of Szeged and 
Csongrád county, to estimate the proportion of the different clinical forms, the relapse rate 
and their neurological condition. These patients give the major proportion among the 
patients cared at the MS outpatient Unit at the Department of Neurology, University of 
Szeged (Paper I and II). 
k-To standardize the conditions of CSF sampling, which samples are later stored at the 
CSF bank, and provide a CSF bank register, where the decoding and the sample collection 
for further clinical trials is easy to handle (Paper III). 
&-In the etiology of MS environmental as well as genetic factors.are involved. Among the 
environmental factors virus infections are most often in connection with the first MS 
relapse. Beside the viruses Ebstein Barr and others, the herpes virus family was found to be 
involved in the pathology of MS. To show the presence of the latent neurotrop members of 
the herpes virus family, the HHV-6 and HHV-7 from sera and CSF of MS patents and 
controls (Paper III). 
&-To study genome-wide screen associations in MS patients in an international survey 
(Paper IV). 
&-To present a case report of an unusual familial aggregation of MS (Paper V). 
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fc-To quantify the intracellular catecholamine levels in the peripheral blood lymphocytes 
of MS patients and controls, presuming that they can be markers of the ongoing 
immunological activity (Paper VI). 
&-To evaluate the conditions of MS patients after 3-years of IFNp-lb therapy, regarding 
relapse rate, progression index, neurological condition and days spent in hospital and 
amount of steroids needed in a year (Paper VII). 
2. Patients and methods 
2.1. Patients 
2.1.1. Patients and methods in the epidemiological studies of Szeged and Csongrád 
county (Paper I and II) 
In Szeged and the surrounding counties (e. g. Csongrád county) the MS Outpatient Unit, 
Department of Neurology, University of Szeged deals with the medical care for MS. The 
number of patients cared at the MS outpatient unit was increasing to the double in the 
middle of the '90s (approximately 600 patients). We estimated the prevalence, the 
incidence, the female:male ratio, the clinical forms according the Poser diagnostic criteria 
(58) and the uniform nomenclature (5), the functional status (69) in Szeged and Csongrád 
county. The medical records at general practitioners, neurological- and ophtalmological 
departments and homes for aged were checked for these studies. The epidemiological data 
were also based on the regularly updated MS register, which is used since 1996. The 
diagnosis of the patients is based on the MRI and CSF findings, and additionally VEP 
results. In Paper I, the number of inhabitants in Szeged on January 7, 1997 was 198,682 
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(Hungarian Central Statistical Office - Központi Statisztikai Hivatal). 130 MS patients 
from Szeged were cared at the MS Outpatient Unit. In Paper II, according to the files of the 
Hungarian Central Statistical Office Szeged City (the Country town of Csongrád County) 
had 198,686 inhabitants, Csongrád County has an additional 222,506 inhabitants. In the 
study 400,128 inhabitants were the representative sample; the population of a small city 
with 21,064 residents was excluded because there were no available data. 
2.1.2. Patients and controls in the HHV-6 study (Paper III) 
The sera-CSF sample pairs were collected from the CSF bank, using the register to find 
MS patients with abnormal CSF results and age-matched controls. Samples of seven RR 
MS patients and 6 patients with other neurological diseases were evaluated. 
2.1.3. Patients and controls in the GAMES study (Paper IV) 
The 88 unrelated MS patients were recruited by the MS Outpatient Unit. The 128 healthy 
blood donors fulfilled the criteria of the regulations of the local ethical committee and all 
patients from the cases group met the Poser's criteria (58). The mean age was 35 years in 
the cases group and the sex was consistent with previous population based series 3.6 
femalrl male. The ratio was 2.6/1 in the unrelated control group. Considering disease 
course, 90% of the patients had RR disease course, and 10% of patients had SP disease. 
2.1.4. Patients and their relatives in the case report (Paper V) 
Three sisters suffering from MS and their healthy parents and grandparents were explored. 
Medical history was taken at the MS Outpatient Unit. Each family member's neurological 
condition was evaluated. At the time of the report the patients were 24, 26 and 27 years 
old. The symptoms of the eldest sister began in 1993 with lower-limb weakness and 
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paraesthesia. Two months after her second labor in March 1998, she was admitted to 
hospital with limb weakness, nystagmus and ataxia. MRI of the brain, the visual, brainstem 
and somatosensory evoked potentials, and CSF examinations verified MS. The middle 
sister exhibited left-side optic neuritis at the initial examinations in February 1998. The 
MRI findings on the head and optic nerve, the CSF examinations and the electrophysiology 
all pointed to MS. Despite a negative neurological condition, the third sister had subjective 
complaints such as paraesthesia of variable intensity in all the extremities and vertigo. The 
MRI of the brain revealed multiple periventricular T2-weighted lesions, and oligoclonal 
bands were detected in the CSF by isoelectric focusing. On the Poser diagnostic criteria 
(58), one of the three sisters was in category Bl, and the others in category B2. Both 
parents and all four grandparents are without neurological signs; the brain MRI 
examinations on the parents were negative. 
2.1.5. Patients and controls in the catecholamine study (Paper VI) 
In total 67 patients were examined and were found to have clinically definitive and 
laboratory-supported definitive MS according to the Poser criteria (58). In the patients 
group 10 subjects were laboratory-supported definitive (first attack) patients, 48 had 
relapsing-remitting course MS. Both the CSF findings (oligoclonal bands with isoelectric 
focusing electrophoresis) and MRI examinations (several periventricular T2-weighted 
lesions) of the first attack patients supported the MS diagnosis. All the relapsing-remitting 
patients were in remission, and none of the patients received steroid therapy within 30 days 
and none of them were on tricyclic antidepressants, cardiac drugs or amantadine. The 
neurological conditions of the patients were expressed in the Kurtzke expanded disability 
status scale (EDSS) (69). Healthy individuals (n=19) served as controls. The ethical 
committee of the Albert Szent-Györgyi Medical School (886/1998) had approved the 
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study. For statistical analysis patient's subgroups were formed according to the a.) clinical 
course of the disease: 1st attack (n=10), relapsing-remitting (n=48); b.) EDSS score: EDSS 
score below (n=49) and above 4.0 (n=9); c.) duration of the disease: less (n=30) and more 
than 5 years (n=28); d.) time to the last relapse: relapse within 6 months (n=19) and more 
than 6 months (n=39). 
2.1.6. Patients oninteferon/3-lb treatment (Paper VII) 
All patients recruited for interferon treatment in between July and November 1996 at the 
MS outpatient unit were involved in this trial. In line with the guidelines of the American 
Academy of Neurology (70) 36 patients have been randomized. All the patients were in the 
laboratory-supported definite MS category according to Poser's diagnostic criteria (58) 
with oligoclonal bands and MRI findings pointing to MS. The male:female ratio was 
10:26. 34 patients had RR and two patients relapsing-progressive course of the disease. 22 
females and 9 males completed the study. Patients received 8 MIU IFN-P-lb sc. every 
other day. EDSS scores have been determined at the beginning of the therapy, monthly and 
in the case of exacerbations before and after the mega-dose steroid treatment. Laboratory 
parameters were controlled (routine urine and blood tests, glucose, ions, kidney and liver 
functional tests) monthly for 3 months, followed by controls every 3rd month. The side 
effects were recorded monthly. In case of an exacerbation the EDSS score before and after 
the steroid treatment and one month after the relapse was determined. The steroid needs 
required to treat relapse and the days of hospitalization were calculated. The relapse-rates 
concerning the 2 years prior the treatment (1995-96) and the three years of the IFN-P-lb 
treatment, were compared together with the EDSS scores respectively. The duration of 
hospitalization, the steroid needs for remissions in 1995-96 and in the three years of 
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therapy were calculated. Statistical analysis was made by one-way ANOVA analysis 
followed by pairwise comparison with Bonferroni. 
2.2. Methods 
2.2.1. Samples from the CSF bank (Paper III) 
Emerging need has become evident for a well-documented and updated CSF bank, where 
the CSF samples are taken at standardized conditions to be comparable. From the end of 
1997 centrifuged sera and CSF pairs were labeled with an encoded uniform label before 
placing it to the -70°C freezer. For decoding a daily updated register is used, containing 
the cell count, and albumin content. The colleagues at the Department of Neurology, 
Neurosurgery and Intensive Care Units, were informed to take equal amounts of CSF (12 
ml recommended) in order to have comparable CSF samples. Previous studies proved a 
protein gradient in the CSF (71, 72). If the amount differs this should be referred on the 
laboratory sheet. This sheet was specially developed in 1997 for the faster processing of 
the CSF from the laboratory to the CSF bank. Instead of handwriting, boxes (e.g. 0 ) were 
of help for the laboratory assistants. The delivery of the CSF occurs immediately after the 
lumbar puncture followed by a phone call for a technician in medicine. From the lumbar 
punction until the storage approximately half-hour is consumed, though sensitive 
molecules in the CSF samples are preserved in this short time period. The CSF was 
centrifuged at low speed, followed by the quantitation of the leukocyte number in the pellet 
(Fuchs, Rosenthal chamber). The supernatant was kept for further analysis in the -70°C 
freezer. The date of the sampling, number of the vials, name, presumed diagnosis and the 
CSF finding on proteins were registered in the diary. 
2.2.2. Cerebrospinalfluid protein analysis (Paper 111 and V) 
The following descriptions of the methods of CSF analysis are routine methods in our 
laboratory using external control (73, 74). Quantitation of the total protein was performed 
by trichloroacetic acid precipitation. 
2.2.3. Laser nephelometry (LN) (Paper III and V) 
The laser scattering method for quantitation of albumin, IgG, IgM and IgA was used 
(Dosascat, Dosatec GmbH, Munich, Germany) (75, 76). All parameters were determined 
simultaneously in CSF and diluted sera by LN. LN antisera, standards and control sera 
were purchased from Dosatec GmbH. Serum dilutions were adapted for CSF calibration 
curves. IgG, IgA, IgM and albumin were measured according the manufacturer's 
instructions for CSF samples. Dilution series were used for the standard curves, the curves 
were modified according the Reiber formula (77). 
2.2.4. Agarose gel electrophoresis and isoelectric focusing (Paper III and V) 
The proteins in the CSF were analyzed using agarose gel electrophoresis and isoelectric 
focusing followed by silver staining, as a routine method in the CSF laboratory at the 
Department of Neurology (78-80). For the detection of IgG bands immunoblot was used 
(81). 
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Figure 1. Agarose gel electrophoresis (CSF and sera pair) with oligoclonal bands in the 
CSF gamma protein region points to intrathecal inflammation in MS. The oligoclonal 
bands are not present in the sera. 
Figure 2. Immunoblotting - detection of IgG oligoclonal bands 
2.2.5. ELISA (Paper III) 
Sensitive ELISA was used to quantify variant specific IgG and IgM, as described (Marodi 
et al., 1998). Briefly, JJHAN cells infected with HHV-6A GS, MOLT-3 cells infected with 
HHV-6B Z29, Sup-Tl cells infected with HHV-7 RK strain served as antigens and were 
fixed to 96 well polystyrene plates, when OHV-1 monoclonal antibody (MAb; Advanced 
Biotechnologies Inc., Columbia, MD, US) to both FIHV-6 variants and RK-4 MAb to 
HHV-7 in indirect immunofluorescent assays detected equal ratio (38 to 40%) of cells 
containing viral antigens. HHV-6 variant specificity was verified by competitive binding of 
anti-HHV-6B 101k MAb (P.E.Pellett, Atlanta, GA, US). Competing IgG was removed 
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from aliquots of each serum and CSF by mixing them with Protein-A Sepharose 4B 
(Sigma, St. Louis, MO, USA) in 10:1 ratio forlh with subsequent low speed centrifugation. 
Twofold dilutions of sera and CSF (1:100 to 1:6400) were incubated with the antigens in 
96 well polystyrene plates in quadruplicate. After vigorous washings, peroxidase 
conjugated anti-human IgG and IgM (Sigma), respectively, were adsorbed to human 
polypeptides in parallel wells, finally orthophenyldiamine substrate was introduced in each 
well. The optical density, read at 492 nm, 150% higher than that of the standard deviation 
of established seronegative subjects were regarded as positive. Sera of known seropositive 
individuals (L. Ceccherini-Nelli, Pisa, D. DiLuca, Ferrara, Italy) served as controls. Serum 
and CSF dilutions at 1:100 were tested in quadruplicate for non-specific binding to 
uninfected cells, but no reactions were detected. 
2.2.6. DNA extraction and pooling (Paper IV) 
Genomic DNA was extracted manually using a standard phenol-chloroform method. The 
concentration was established measuring the optical density twice; only samples with less 
than 10% difference in these measures were included. Each sample was then diluted to a 
concentration of 50 ng/uL. Pools (patients and controls) were constructed by combining 
equal volumes from contributing samples. 
2.2.7. Genotyping (Paper IV) 
All markers were amplified in each of the 2 pools using standard polymerase chain 
reaction (PCR) protocol according to the manufactures recommended conditions. PCR 
products were electrophoresed twice (82) using an Applied Biosystems 3700 DNA 
Analyser (Applied Biosystems) and sized using Applied Biosystems GENES CAN 
software (version 3.5). The allele image patterns (AIPs) generated were analyzed using the 
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perl program ALLELPICKER which was specifically written for the GAMES project. This 
program avoids the need to inspect the AIPs in GENOTYPER and is thus considerably 
more efficient. On the other hand the program is critically dependent on the sizing 
algorithm, such that any error in this can result in erroneus data being collected. In order to 
identify such errors all AIPs from markers showing significant results were inspected 
manually with GENOTYPER. 
2.2.8. Preparation of Lymphocytes (Paper VI) 
Peripheral vein blood samples (12 mL) were prepared by centrifugation at 2500xg for 10 
minutes. Lymphocytes were isolated by centrifugation on a Lymphoprep® (Nycomed 
Pharma, Oslo, Norway) density gradient and after washing and centrifugation steps kept in 
-80° C until analysis. Lymphocytes were extracted by adding 25 uL perchloric acid 
(containing 1 mM NaEDTA and ImM Na2S03) to the pellet and ultrasonicated on ice for 2 
minutes using a MSE Soniprep 150 probe. After centrifugation (30 min, 4°C, 35000xg) the 
supernatant was frozen and stored in -80°C until analysis. The pellet was used for 
spectrophotometric protein quantitation using bicinchoninic acid protein assay reagent 
(BCA, Pierce Chemical Company, USA). 
2.2.9. Capillary Electrophoresis with Electrochemical Detection (Paper VI, Figure 6) 
The capillary electrophoretic system used has earlier been described in detail (56, 83), but 
briefly a buffer filled fused silica capillary (Polymicro Technologies, Phoenix) with 10 um 
i.d. and of 65 cm length was placed between two buffer reservoirs. High voltage was 
applied at the injection end, and the reservoir containing the outlet detection end was held 
at ground potential. Electrokinetic injection was used for all sample introductions, 5s at 30 
kV, sample volume was approximately 600 pL. The easily oxidized analytes were detected 
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in the amperometric mode with a two-electrode configuration using the optimized end-
column detection (84). Carbon-fiber microelectrode was inserted into the end of the 
electrophoresis capillary and held at 0.8 V versus a sodium-saturated calomel electrode. 
Reagents: 2-(N-Morpholino) ethanosulfonic acid (MES), serotonin (5-HT), NE, E, DA, L-
hydroxylphenylalanine (L-DOPA), VMA, MHPG, HVA and dihydroxyphenylacetic acid 
(DOPAC) were obtained from Sigma and used in the form received. The electrophoresis 
buffer was 25 mM MES adjusted to pH 5.65 with NaOH. Calibration standards were 
prepared as 10 mM stock solution in 0.1 M perchloric acid and diluted to the desired 
concentration in electrophoresis buffer. Hydrofluoric acid was obtained as a 40% aqueous 
solution from Aldrich, and used for the etching of the detector end of the capillary. 
Catecholamine levels of lymphocytes have been quantified by direct comparison with the 
standard electropherograms run before and after the patients' sample. The catecholamine 
content of the lymphocytes is given in finol/ug protein. Detection limits were determined 
(for dopamine, norepinephrine 0.13 finol/ug protein, for epinephrine 0.37 finol/ug protein, 
and for DOPAC 0.11 finol/ug protein) and estimated at twice the peak-to-peak noise level 
by extrapolation from plots of peak area versus concentration. In between the series of 
runs, the capillary was flushed with 0.1 M NaOH to refresh the inner capillary surface and 
to maintain reproducible separation conditions. For more detailed description of the 
method see Bergquist et al. (55). 
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T i m e (min) 
Figure 3. A representative electropherogram of catecholamines extracted from human 
peripheral blood lymphocytes showing the peaks of dopamine (DA), norepinephrine (NE), 
epinephrine (E), neutral species (N), uric acid (UA) and dihydroxyphenylacetic acid 
(DOPAC). 
2.3 Statistics 
2.3.1. Statistical analysis of the GAMES study (Paper IV) 
Since each microsatellite marker was amplified once by PCR and electrophoresed twice, 
two replicate AIPs were generated from each of the 2 pooled samples. Best fit AIPs were 
calculated for both the cases and controls, normalized according to the total number of 
• . 9 
alleles in the respective pools and compared statistically a Chi test. Alleles with a 
frequency of <5% were considered together. Given that the majority of typed markers are 
not expected to be associated with MS we were able to use the observed distribution of 
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Chi2 results in order to correct the additional sources of variance introduced by pooling. 
This process was completed using the software package specifically developed for 
GAMES. The empirical p-values thus calculated enable the typed markers to be ranked 
according to their evidence for association. Data was analyzed incorporating the adapting 
factors suggested by Yeo et al. (85). For more details about the statistical analysis see 
Setakis et al. (86). 
2.3.2. Statistical analysis of the intracellular catecholamines (Paper VI) 
Kruskall Wallis test (SPSS 7.5 for Windows) was performed for statistical analysis to 
compare the catecholamine levels in healthy controls and the subgroups of MS patients, 
followed by Mann Whitney U test for pairwise comparison to see the differences between 
patients and healthy controls. Furthermore, Kruskal Wallis test was used for the statistical 
analysis of differences between the healthy controls and the different MS subgroups 
(regarding EDSS score, medication, and duration). 
3. Results 
0 Epidemiological data were evaluated based on the patients data cared at the MS 
Outpatient, Unit Department of Neurology, University of Szeged, Hungary. We calculated 
the prevalence, incidence, and the percentage of the different clinical forms in the city of 
Szeged, and the county Csongrád (Paper I and II). The data are shown in Table 1. 
Our data are comparable to the international data, and are a reliable background for 
planning other studies where MS patients are involved. 
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Table 1. Comparison of the epidemiological data in the city of Szeged and Csongrád 
county 
Epidemiological data City of Szeged Csongrád county 
Prevalence 
Male: female ratio 
Mean age at onset (all forms) 
Clinical course 
-benign 
-RR 
-SP 
-PP 
-RP 
EDSS 
EDSS (0) 
EDSS (1-4) 
EDSS (4.5-6.5) 
EDSS (=7) 
EDSS (>7) 
Incidence in Szeged 
65/100000 (Dec. 31,1996) 
1:3 
35 years 
4% 
80% 
4% 
11% 
1% 
All forms (N=130) 
21% 
57% 
16% 
2% 
4% 
7/100000 (1996) 
5/100000 (1997) 
6/100000 (1998) 
62/100000 (July 1,1999) 
1:2.75 
29.5 years 
15% 
54% 
20% 
11% 
NP 
RR patients (N=82) 
27% 
EDSS (0-4): 60% 
33% 
NP 
7% 
NP- data not published 
0 The CSF sampling was standardized, new laboratory sheet was introduced, the samples 
were provided with uniform encoded labels, and the CSF bank has an updated register. 
0 In MS patients, the oligoclonal bands, protein content, nephelometry and presence of 
variant specific antibodies showed a considerable correlation (Table 2). Predominance in 
the positivity of IgG (6/9=67%) and IgM (4/9=44%) to HHV-6B over IgG (4/9=44%) 
with no detectable IgM to HHV-6A was found. This raises the possibility that past HHV-
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6A infection silent at time of test, and chronic active or primary HHV-6B infection 
(especially in cases 2, 5, 6, and 7) might contribute to MS. On the contrary, lack of 
antibodies in CSF to HHV-7 can exclude its role in MS. As seven of nine patients had 
antibodies to HHV-7 in their sera (data not shown), this also demonstrates integrity of 
BBB. No antibodies to HHV-6 and HHV-7 were found in the youngest MS patients (1 and 
5), which might suggests involvement of another agent(s) in triggering disease. In other 
neurological disorders, CSF contained no detectable antibodies to HHV-6 or HHV-7. In 
patient 13, HSV-1 was identified as a causative agent of encephalitis. In the serum and 
CSF of MS patients we found HHV-6A viruses more often. These data suggest that latent 
virus replication as environmental factor might be implicated in the induction or 
pathogenesis of the disease (Paper III). 
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Table 2. Antibodies to HHV-6 and HHV-7 in CSF of patients with MS and other 
neurological disorders (ELISA) 
No. Age Sex Clinical Leukoc Protein Nephelometry OCB HHV-6 HHV-6 HHV-7 
Years M/F form 106/1 g/1 IgG IgM IgG IgM IgG IgM 
Antibody titres 
1 25 M RR 1 0.26 - + 0 0 0 0 0 0 
2 29 M RR 45 0.38 IgM, IgG + 0 0 800 400 0 0 
3 34 M RR 0 0.22 IgA, IgM, IgG + 400 0 100 0 0 0 
4 53 M RR 1 0.54 IgG (traces) + 0 0 100 0 0 0 
5 34 F RR 0 0.26 IgG + 0 0 200 200 0 0 
6 36 F FA 0 0.41 IgA, IgM - 200 0 200 100 0 0 
7 41 F RR 5* 0.20 IgG + 400 0 800 200 0 0 
Other neurological disorders 
8 42 M IDR 0 0.40 IgM - 0 0 0 0 0 0 
9 43 M CHA 0 0.39 ND - 0 0 0 0 0 0 
10 50 M CHA 1 0.30 - - 0 0 0 0 0 0 
11 31 F AHE 100** 0.86 IgA, IgM, IgG 
(traces) 
- 0 0 0 0 0 0 
12 25 F PNP 0 0.17 IgM, IgG + 0 0 0 0 0 0 
13 22 F PNP 21 0.47 IgG + 400 0 0 0 0 0 
RR = relapsing-remitting; FA = first attack; IDR = intervertebral disc rupture; CHA = 
chronic headache; AHE = acute HSV-1 encephalitis; PNP = polyneuropathy; ND = not 
determined; *64 and **104 erythrocytes (106/L), 0 = <100. 
0 In an international genome-wide screen for association in MS, the susceptibility to MS 
in Hungarian patients was studied. In the Hungarian population we have identified 33 
potentially associated markers. Six of the markers were from regions previously identified 
by linkage analyses: D3S3571, D5S2102, D7S2516, D7S630 (87), DXS6807 (88) and 
DXS1223 (89) and the rest were from novel regions not previously identified (Paper IV, 
Table 3). 
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Table 3. Empirical p-values for the top 20 markers. 
Locus Chr p-value Mb *LocusIink * localisation 
D16S3097 16 0,006 78,35 
D7S6308 7 0,013 86,98 
D19S9218 19 0,015 54,13 VN1R4 19ql3.42 
DXS6807 X 0,017 3,57 
D6S275 6 0,019 93,03 
D9S1853 9 0,02 30,03 
D2S338 2 0,022 235,92 
D3S1283 3 0,029 28,21 Marfan sy 3p25-p24.2 
D14S281 14 0,029 48,9 KIAA1053 protein 
D20S892 20 0,03 6,7 
D18S11278 18 0,032 53,27 
D6S424 6 0,035 95,49 
D3S35718 3 0,036 63,79 
D7S2516 7 0,037 69,75 
D8S1762 8 0,038 101,53 Cohen sy 1 8q22-23 
D1S2677 X 0,038 46,1 
D20S891 20 0,04 45,62 PKBP1 20ql3.12 
D10S1669 10 0,042 43,59 
D5S502 5 0,043 26,12 
D5S2045 5 0,044 169,03 
8 These markers were included in the 529 considered by Yeo et al. 
*data found at the www.nih.gov website for these markers 
0 We reported a case of multiplex MS family with three affected sisters. In this unusual 
case all the two parents and four grandparents were healthy, without any neurological 
disorder (Paper V). 
0 Using capillary electrophoresis with electrochemical detection catecholamines were 
measured in the peripheral blood lymphocytes of RR MS patients. First attack MS patients 
had higher intracellular epinephrine levels (p=0.028) compared to the controls, while 
decreased norepinephrine concentration (p=0.027) was detected in the stable RR MS group 
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compared to first attack MS patients. The increased epinephrine level might be due to the 
activated immune system. The smaller amount of norepinephrine in the PBL of the stable 
RR MS group suggest a clinically and immunologically stable phase of the disease (Paper 
VI). These findings are in line with our other study (Rajda et al. ECTRIMS 2001, abstract). 
0 Finally we reported our experiences of immunomodulant therapy (interferon(3-lb) in a 
three-year follow-up open labeled study, where the relapse-free proportion was higher than 
in the previous placebo-controlled studies (Paper VII). This was in line with other 
published open-labeled studies (Table 4). 
Table 4. Differences observed during the 3 years of IFNP-lb treatment (mean±SD) 
1995 1996 1997 1998 1999 
No. of relapses / patient 1.0±0.5 1.6±0.6 0.4±0.5 0.4±0.4 0.2±0.4 
Days of hospitalization/ patient 14±10 18±11 3.5±6.8 3.1±5.2 0.7±2.1 
Need of steroid (g)/patient 4.3±2.8 7.0±2.5 1.7±2.9 1.7±2.4 0.6±1.6 
Data given as mean±SEM 
4. Discussion 
4.1 The role of epidemiologicalfindings 
Epidemiological studies are of great help in finding etiological factors in different 
disorders, such as multiple sclerosis. The diagnostic criteria of multiple sclerosis have 
recently improved, and the prevalence of this disease can now be determined more 
precisely. Epidemiologists in many countries worldwide were reanalyzing the prevalence 
of multiple sclerosis (7-9, 90-99). These studies highlighted both environmental and 
genetic factors implicated in this disease. Among Japanese patients Devic's neuromyelitis 
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optica is more common than among the Caucasian patients pointing to genetic 
predisposition (100), while the seasonally increased MS incidence at Faroe Islands suggest 
environmental influence in the pathogenesis of the disease (97). Our findings in Paper I 
and II are in line with the findings of other epidemiological studies at the same latitudes, 
and made our data comparable to the literature. 
4.2. Environmental factors - the role of viruses 
Both HHV-6 (101) and HHV-7 (102) induce intrathecal synthesis of IgM and IgG. Until 
the breakdown of BBB in the later stage of disease, variant specific antibodies primarily in 
the CSF (101) and secondarily in the serum (32, 103-105) might indicate disease 
progression. Significant correlation was reported between levels of soluble CD46 (cellular 
receptor for HHV-6) in the serum and cerebrospinal fluid of multiple sclerosis patients 
(106). Presence of CSF antibodies in different titers suggests different roles of HHV-6 
variants, while the absence of CSF antibodies to HHV-7 seems to exclude its intrathecal 
contribution to the pathogenesis of MS. In few cases, detection of low level IgG without 
IgM to HHV-6 indicates past infection without recent expression of viral genes. We found 
HHV-6A antibodies more often in MS patients than controls suggesting a possible role of 
these viruses in the initialization or in the pathogenesis of the disease. 
4.3. Genetically determined susceptibility 
Three independent genome screens typed a set of microsatellite markers covering the 
genome. Only 43 markers were common to all the three screens (107). In our study, from 
the 33 associated markers only six were from regions previously identified by linkage 
analyses: D3S3571, D5S2102, D7S2516, D7S630 (87), DXS6807 (88) and DXS1223 (89) 
and the rest were from novel regions not previously identified. Large population-based 
> 
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studies and populations containing the affected genes more often (multiplex families), than 
the general populations are needed to find the genes of interest in MS. Careful descriptions 
of familial aggregation and collection of data and DNS samples from these families could 
be helpful in searching for the cause of genetic susceptibility in MS. 
4.4. The role of norepinephrine in the immune responses 
Alterations have been described in sympathetic nervous system regulation of immune 
function, including decreased serum norepinephrine levels in RR MS patients in relapse 
(108), higher baseline serum levels of dopamine, norepinephrine and epinephrine in RR 
MS patients (109), elevated norepinephrine levels in the CSF (110), and altered ic. 
norepinephrine levels (109, 111). The increase in catecholamine levels due to physical 
stress were similar in MS patients as compared to healthy controls (112). The activation of 
the sympathetic nervous system seems to be associated with clinical activity in RR MS 
(112, 113), while the norepinephrine in the plasma revealed to be biochemically stable in 
healthy volunteers (114). In vivo evidence for an immunosuppressive role of 
norepinephrine is based on animal and neuropathological studies. Norepinephrine 
modulates inflammatory gene expression in vitro, inhibiting the expression of genes of 
NOS2, adhesion molecules, class IIMHC, IL-10, TNF-a (as reviewed by Feinstein, 2002) 
(115). This evidence provides additional support to the idea that the CNS can modulate 
inflammatory and immune reactions both centrally and in the periphery. The inhibitory 
actions of norepinephrine may be mediated primarily within the nucleus affecting the 
N F K B : I K B system (115). Based on numerous studies, norepinephrine may regulate early 
immune events as antigen localization, presentation, B cell activation or inhibition of T 
suppressor cell activation and regulate both Thl and Th2 cell function (116, 117). 
Norepinephrine may also suppress normal immune response (51). Elevated levels of 
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norepinephrine were observed in CSF but not in the blood of MS patients (118). A 
hypothesis states that there is a deficiency of norepinephrine in the nerve terminals in MS 
similar to the dopamine deficiency in the Parkinson disease patients. This hypothesis is 
supported by the fact that near the fourth ventricle lies the locus ceruleus, a norepinephrine 
mediated part of the brain regarded as a "stress center". Lower levels of norepinephrine in 
MS could maybe explain the reduced awareness and memory function, difficulties with 
miction and cerebellar symptoms which are the opposite of the "fight or flight" reactions 
(119). We observed higher intracellular levels of epinephrine in first-attack MS patients, 
and the lymphocytes express primarily p-adrenergic receptors. Thus, we can propose the 
following hypothesis, presented schematically in Figure 5. An increased level of E 
activates the lymphocytes; they cross the BBB and find their antigens. This process is 
followed by the production of cytokines, which either result in an inflammatory process or 
act as the major compartment in the relapse process. A relapse-increased p-receptor 
density on the lymphocytes has been described, lending support to our hypothesis. It is not 
clear whether the lymphocytes merely mirror the state of the disease, reflecting the altered 
hypothalamus-pituitary gland-adrenal medulla (HPA) axis function and drain the 
catecholamines from the plasma, or are active participants, eliminating the catecholamines 
by uptake and degradation or releasing them into the MS plaque. The lower level of NE in 
the peripheral blood lymphocytes of RR MS patients in remission could be due to the P-
adrenergic receptor down-regulation after a bout or to the degradation of the 
catecholamines. Remission may be due to a general down-regulation of the immune 
response by immunologically nonspecific mechanisms, such as the endogenous secretion 
of corticosteroids. Later in the disease process, a negative feedback suppresses the 
production of the catecholamines, resulting in a decreased catecholamine content of the 
peripheral blood lymphocytes during remission. This may explain why RR MS patients in 
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remission may have lower levels of catecholamines such as NE and also account for the 
neuroimmunological entity of the relapse. Relapses can be induced by infection, stress, or 
an elevated level of E, which activates the lymphocytes, resulting leading in turn to 
activation of the disease. MS patients have a significantly lower NE content in their 
peripheral blood lymphocytes than that for healthy individuals, but in the early stage of the 
disease, and hence in first-attack patients, the E content is higher. With regard to the fact 
that the lymphocytes in relapse have a higher P-receptor density, new means of early 
intervention in the pathogenesis of MS at the lymphocyte level may be possible. 
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© ( Thl-activation 
© epinephrine ft 
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Blood brain barrier 
Figure 4. A hypothetical role of the catecholamines in the pathogenesis of MS. CD Thl T 
cell activation takes place in the periphery. © Increased epinephrine levels activating the 
lymphocytes augment their entrance through the BBB.® Well inside the CNS, the 
lymphocytes find their antigens and are further activated. © After the activation of the 
lymphocytes, a feedback process is initiated. © This feedback loop leads to lymphocyte 
deactivation and the epinephrine content of the lymphocytes is decreased. This epinephrine 
decrease is then followed by an increase in norepinephrine, causing a down-regulation of 
the lymphocytes ©, and leading to the steady state of remission. 
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4.5. IFNfi-lb therapy in RR MS patients 
IFNP-lb (Betaferon ®) is a non-glycosilated recombinant human P-IFN produced in 
Escherichia coli bacteria, administered every other day sc. in 8 MIU dosages. At the 
double dose given to healthy volunteers, serum concentrations reached a peak of 40 
MIU/mL within 1 to 8 hours, with a bioavailability of 51% (120). The serum 
concentrations were observed to peak 8 to 24 hours after sc. administration of 8 MIU (120 
to 475 IU/mL) in patients with MS. In an open-label follow-up study we reported on 
sustained benefit of the immunomodulant treatment, which was in line with other open-
label follow-up studies (121). 
Acknowledgements 
I would like to express my gratitude to those who, in so many different ways, helped me 
with this thesis, particularly: My Supervisor László Vécsei for all the encouragement and 
continued support; My Co-Supervisor Krisztina Bencsik for so generously sharing all her 
knowledge and skill in multiple sclerosis and neurology; My Extra-Supervisor Jonas 
Bergquist for introducing me to the field of biomedical research, inspiring discussions and 
hot glögg after skating on one of the most wonderful Swedish lakes. Alastair Compston, 
Aslaug Jonasdottir, Ragnheidur Fossdal, Stephen Sawcer, Thomas Foltynie, Kjartan 
Benediktsson, Efirosini Setakis for fuitful collaboration. All friends of the Department of 
Neurology in alphabetical order: György Dibó, Judit Füvesi, Tamás Járdánházy, Péter 
Klivényi and Erika Seres for good company and fruitful collaboration. Krisztina Boda for 
her help with statistical evaluation. Erika Vörös for helpful instructions interpreting 
questionable brain MR-images, Márta Janáky for VEP analyzes. József Ongrádi and Csaba 
Maródi for fruitful collaboration. Rolf Ekman for inspiring discussions. Margit Török, 
Lászlóné Nagy, Rita Persson and Péterné Szűcs for excellent technical assistance. 
And of course special thanks to my family, for their love, patience and constant support. 
Swedish Institute stipend grant No. 504/1998 is gratefully acknowledged. 
References 
1. Butler MA, Bennett TL. In search of a conceptualization of multiple sclerosis: a 
historical perspective. Neuropsych Rev 2003;13:93-112. 
2. Charcot JM. Histologic de la sclerose en plaques. Gazette des Hopitaux (Paris) 
1868;41:554-566. 
3. Babinski J. Etude anatomique et clinique sur la sclerose en plaques. Paris, 1885. 
4. Környey I. Neuropathologia. Budapest: Medicina Könyvkiadó, 1987. 
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an 
international survey. National Multiple Sclerosis Society (USA) Advisory Committee on 
Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911. 
6. Gonzalez O, Sotelo J. Is the frequency of multiple sclerosis increasing in Mexico? J 
Neurol Neurosurg Psych 1995;59:528-530. 
7. Bufill E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in the region of 
Osona, Catalonia, northern Spain. J Neurol Neurosurg Psych 1995;58:577-581. 
8. Cavalletti S, Merelli E, Cavazzuti M, Guidetti D. Frequency of MS in the province of 
Modena, 1970-1990. Acta Neurol Scand 1994;90:377-381. 
9. Bansil S, Singhal BS, Ahuja GK, Ladiwala U, Behari M, Friede R, et al. Comparison 
between multiple sclerosis in India and the United States: a case-control study. Neurology 
1996;46:385-387. 
34 
10. Pálffy G, Czopf J, Kuntár L, Gyódi É. Multiple sclerosis in Baranya County in 
Hungarians and Gypsies. In: Firnhaber W, Lauer K eds. Multiple sclerosis in Europe: an 
epidemiological update. Darmstadt: Leuchtturm Verlag/LTV Press, 1994: 274-278. 
11. Miller DH, Homabrook RW, Dagger J, Fong R. Ethnic and HLA patterns related to 
multiple sclerosis in Wellington, New Zealand. J Neurol Neurosurg Psych 1986;49:43-46. 
12. Gronning M, Mellgren SI. Multiple sclerosis in the two northernmost counties of 
Norway. Acta Neurol Scand 1985;72:321-327. 
13. Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. 
VIII. Long-term survival after onset of multiple sclerosis. Brain 2000;123:1677-1687. 
14. Dean G, Bhigjee AI, Bill PL, Fritz V, Chikanza IC, Thomas JE, et al. Multiple sclerosis 
in black South Africans and Zimbabweans. J Neurol Neurosurg Psych 1994;57:1064-1069. 
15. Oger J, Lai H. Demyelination and ethnicity: experience at the University of British 
Columbia Multiple Sclerosis Clinic with special reference to HTLV-I-associated 
myelopathy in British Columbian natives. Ann Neurol 1994;36:22-24. 
16. Guseo A, Jófejű E, Kocsis A. Epidemiology of multiple sclerosis in western Hungary 
1957-1992. In: Firnhaber W, Lauer K eds. Multiple sclerosis in Europe: an 
epidemiological update. Darmstadt: Leuchtturm Verlag/LTV Press, 1994: 279-286. 
17. Dean G. Epidemiology of multiple sclerosis. Neuroepidemiology 1984;3:58-73. 
18. Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol 
1994;36:180-193. 
19. Sadovnick AD. The genetics of multiple sclerosis. Clin Neurol Neurosurg 
2002;104:199-202. 
20. Sadovnick AD. Genetic epidemiology of multiple sclerosis: a survey. Ann Neurol 
1994;36:194-203. 
35 
21. Sadovnick AD, Risch NJ, Ebers GC. Canadian collaborative project on genetic 
susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group. 
Can J Neurol Sci 1998;25:216-221. 
22. Sadovnick AD, Yee IM. Season of birth in multiple sclerosis. Acta Neurol Scand 
1994;89:190-191. 
23. Weinshenker BG. Epidemiologic strategies to detect an exogenous cause of MS. Acta 
Neurol Scand 1995; 161:93-99. 
24. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: 
relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302. 
25. Owens T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause 
heterogeneous dysfunction and damage. Curr Opin Neurol 2003;16:259-265. 
26. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple 
sclerosis: relationship to relapses, EDSS, and treatment with interferon p-la. Multiple 
Sclerosis 2000;6:365-372. 
27. Zivadinov R, Sepcic J, Nasuelli D, De-Masi R, Bragadin LM, Tommasi MA, et al. A 
longitudinal study of brain atrophy and cognitive disturbances in the early phase of 
relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psych 2001;70:773-780. 
28. Hafler DA. The distinction blurs between an autoimmune versus microbial hypothesis 
in multiple sclerosis. J Clin Invest 1999;104:527-529. 
29. Lucchinetti C, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in 
neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr 
Opin Neurol 2001;14:259-269. 
30. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis 
pathogenesis: implications for diagnosis and therapy. Trends Molec Med 2001;7:115-121. 
36 
31. Swanborg RH, Whittum-Hudson JA, Hudson AP. Infectious agents and multiple 
sclerosis - are Chlamydia pneumoniae and human herpes virus 6 involved? J 
Neuroimmunol 2003;136:1-8. 
32. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Calabresi PA, et al. Association 
of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to 
HHV-6 early antigen and detection of.serum HHV-6 DNA. Nat Med 1997;3:1394-1397. 
33. Fillet AM, Lozeron P, Agut H, Lyon-Caen O, Liblau R. HHV-6 and multiple sclerosis. 
Nat Med 1998;4:537-538. 
34. Hall CB, Caserta MT, Schnabel KC, Long C, Epstein LG, Insel RA, et al. Persistence 
of human herpesvirus 6 according to site and variant: possible greater neurotropism of 
variant A. Clin Infect Dis 1998;26:132-137. 
35. Portolani M, Leoni S, Guerra A, Cermelli C, Mantovani G, Pietrosemoli P, et al. 
Human herpesvirus-7 DNA in cerebrospinal fluid. Min Pediat 1998;50:39-44. 
36. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, et al. 
Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad 
Sei USA 1995;92:7440-7444. 
37. Luppi M, Barozzi P, Maiorana A, Marasca R, Torelli G. Human herpesvirus 6 infection 
in normal human brain tissue. J Infect Dis 1994;169:943-944. 
38. Encinas JA, Kuchroo VK. Mapping and identification of autoimmunity genes. Curr 
Opin Immunol 2000;12:691-697. 
39. Sadovnick AD, Baird PA, Ward RH. Multiple sclerosis: updated risks for relatives. Am 
J Med Gen 1988;29:533-541. 
40. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in 
multiple sclerosis. Canadian Collaborative Study Group. Nature 1995;377:150-151. 
37 
41. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve—an integrative 
interface between two supersystems: the brain and the immune system. Pharmacol Rev 
2000;52:595-638. 
42. Sanders VM, Straub RH. Norepinephrine, the P-adrenergic receptor, and immunity. 
Brain Behav Immun 2002;16:290-332. 
43. Karaszewski JW, Reder AT, Anlar B, Kim WC, Arnason BGW. Increased lymphocyte 
P-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, 
CD28- suppressor cell. Ann Neurol 1991;30:42-47. 
44. Zoukos Y, Leonard JP, Thomaides T, Thompson AJ, Cuzner ML. Beta-adrenergic 
receptor density and function of peripheral blood mononuclear cells are increased in 
multiple sclerosis: a regulatory role for cortisole and interleukin-1. Ann Neurol 
1992;31:657-662. 
45. Zoukos Y, Thomaides TN, Kidd D, Cuzner ML, Thompson A. Expression of p2 
adrenoreceptors on peripheral blood mononuclear cells in patients with primary and 
secondary progressive multiple sclerosis: a longitudinal six month study. J Neurol 
Neurosurg Psy 2003;74:197-202. 
46. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective 
suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents 
induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 
1993;23:1745-1751. 
47. Wiegmann K, Muthyala S, Kim DH, Arnason BGW, Chelmika-Schorr E. Beta-
adrenergic agonist suppress chronic/relapsing experimental allergic encephalomyelitis 
(CREAE) in Lewis rats. J Neuroimmunol 1995;56:201-206. 
48. De Keyser J, Wiczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack P-2 
adrenergic receptors. Neurology 1999;53:1628-1633. 
38 
49. Zeinstra E, Wilczak N, Streefland C, De-Keyser J. Astrocytes in chronic active 
multiple sclerosis plaques express MHC class II molecules. Neuroreport 2000; 11:89-91. 
50. Takamoto T, Hori Y, Koga Y, Toshima H, Hara A, Yokoyama MM. Norepinephrine 
inhibits human natural killer cell activity in vitro. Int J Neurosci 1991;58:127-131. 
51. Bergquist J, Silberring J. Identification of catecholamines in the immune system by 
electrospray ionization mass spectrometry. Rapid Comm Mass Spectr 1998;12:683-688. 
52. Musso NR, Brenci S, Indiveri F, Lotti G. Acetylcholine-induced, calcium-dependent 
norepinephrine outflow from human peripheral lymphocytes. J Neuroimmunol 
1998;87:82-87. 
53. Bergquist J, Ohlsson B, Tarkowski A. Nuclear factor-kB is involved in the 
catecholaminergic suppression of immunocompetent cells. Ann NY Acad Sci 
2000;917:281-289. 
54. Hilliard B, Samoilova EB, Liu TS, Rostami A, Chen Y. Experimental autoimmune 
encephalomyelitis in NF-kappa B-deficient mice: roles of NF-kappa B in the activation and 
differentiation of autoreactive T cells. J Immunol 1999;163:2937-2943. 
55. Bergquist J, Tarkowski A, Ekman R, Ewing A. Discovery of endogenous 
catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte 
function via an autocrine loop. Proc Natl Acad Sci USA 1994;91:12912-12916. 
56. Bergquist J, Tarkowski A, Ewing A, Ekman R. Catecholaminergic suppression of 
immunocompetent cells. Immunol Today 1998;19:562-567. 
57. Mann MB, Wu S, Rostamkhani M, Tourtellotte W, MacMurray JP, Comings DE. 
Association between the phenylethanolamine N-methyltransferase gene and multiple 
sclerosis. J Neuroimmunol 2002;124:101-105. 
58. Poser CM, Paty DW, Scheinberg L. New diagnostic criteria for multiple sclerosis: 
guidelines for research protocols. Ann Neurol 1983; 13:227-231. 
39 
59. McDonald WI, Compston A, Edan G, Goodkin D, Härtung HP, Lublin FD, et al. 
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International 
Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127. 
60. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic 
resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-
24. 
61. Lamoureux G, Jolicoeur R, Giard N, St. Hilaire M, Duplantis F. Cerebrospinal fluid 
proteins in multiple sclerosis. Neurology 1975;25:537-546. 
62. Glasner H. Barrier impairment and immune reaction in the cerebrospinal fluid. Eur 
Neurol 1975;13:304-314. 
63. Blennow K, Skoog I, Wallin A, Wikkelsö C, Fredman P. Immunoglobulin M in 
cerebrospinal fluid: reference values derived from 111 healthy individuals 18-88 years of 
age. Eur Neurol 1996;36:201-205. 
64. Johnson KP, Arrigo SC, Nelson BJ, Ginsberg A. Agarose electrophoresis of 
cerebrospinal fluid in multiple sclerosis. A simplified method for demonstrating 
cerebrospinal fluid oligoclonal immunoglobulin bands. Neurology 1977;27:273-277. 
65. Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et 
al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol 
NeurosurgPsy 1994;57:897-902. 
66. The IFNB Multiple Sclerosis Study Group. Interferon ß-lb is effective in relapsing-
remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, 
placebo-controlled trial. Neurology 1993;43:655-661. 
67. Paty DW, Li DK. Interferon ß-lb is effective in relapsing-remitting multiple sclerosis. 
II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled 
40 
trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. 
Neurology 1993;43:662-667. 
68. Milo R, Panitch H. Glatiramer acetate or interferonP for multiple sclerosis? A guide to 
drug choice. CNS Drugs 1999;11:289-306. 
69. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability 
status scale (EDSS). Neurology 1983;43:655-661. 
70. Report of the Quality Standards Subcommittee of the American Academy of 
Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment 
with Betaseron. Neurology 1994;44:1537-1540. 
71. Blennow K, Wallin A, Gottfries CG, Mansson JE, Svennerholm L. Concentration 
gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm 
1993;5:5-15. 
72. Blennow K, Wallin A, Gottfries CG, Karlsson I, Mansson JE, Skoog I, et al. 
Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. 
Eur Neuropsychopharmacol 1993;3:55-61. 
73. Reiber H. External quality assessment in clinical neurochemistry: survey of analysis for 
cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chemistry 
1995;41:256-263. 
74. Reiber H, Thompson EJ, Grimsley G, Bernardi G, Adam P, Monteiro de Almeida S, et 
al. Quality assurance for cerebrospinal fluid protein analysis: international consensus by an 
Internet-based group discussion. Clin Chem Lab Med 2003;41:331-337. 
75. Kjellin KG, Hallander LB. Determination of CSF proteins by a simple and rapid 
immunonephelometric method. J Neurol 1980;223:35-42. 
76. Liu TZ, Sun CF. Laser nephelometric quantitation of protein in urine and cerebrospinal 
fluid. J Form Med Assoc 1990;89:1067-1071. 
41 
77. Reiber H. The discrimination between different blood-CSF barrier dysfunctions and 
inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of 
cerebrospinal fluid. J Neurol 1980;224:89-99. 
78. Kerényi I. Liquor agarózgél elektroforézis (CSF gel electrophoresis). Ideggyógyászati 
szemle (Clinical Neuroscience) 1977;30:78-80. 
79. Keir G, Luxton RW, Thompson EJ. Isoelectric focusing of cerebrospinal fluid 
immunoglobulin G: an annotated update. Ann Clin Biochem 1990;27:436-443. 
80. Sharief MK, Thompson EJ. Distribution of cerebrospinal fluid oligoclonal IgM bands 
in neurological diseases: a comparison between agarose electrophoresis and isoelectric 
focusing. J Neurol Sci 1992;109:83-87. 
81. Kaiser R. Affinity immunoblotting: rapid and sensitive detection of oligoclonal IgG, 
IgA and IgM in unconcentrated CSF by agarose isoelectric focusing. J Neurol Sci 
1991;103:216-225. 
82. Sawcer S, Maranian M, Setakis E, Curwen V, Akesson E, Hensiek A, et al. A whole 
genome screen for linkage disequilibrium in multiple sclerosis confirms disease 
associations with regions previously linked to susceptibility. Brain 2002;125:1337-1347. 
83. Josefsson E, Bergquist J, Ekman R, Tarkowski A. Catecholamines are synthetized by 
mouse lymphocytes and regulate function of these cells by induction of apoptosis. 
Immunology 1996;88:140-146. 
84. Bergquist J, Josefsson E, Tarkowski A, Ewing A, Ekman R. Measurements of 
catecholamine-mediated apoptosis of immunocompetent cells. Electrophoresis 
1997;18:1760-1766. 
85. Yeo TW, Roxburgh R, Maranian M, Singlehurst S, Gray J, Hensiek A, et al. Refining 
the analysis of a whole genome linkage disequilibrium association map: the United 
Kingdom results. J Neuroimmunol 2003;143:53-59. 
42 
86. Setakis E. Statistical analysis of the GAMES studies. J Neuroimmunol 2003; 143:47-
52. 
87. Haines JL, Ter-Minassian M, Bazyk A, Gusella JF, Kim DJ, Terwedow H et al. A 
meta-analysis of genomic screens in multiple sclerosis. The Transatlantic Multiple 
Sclerosis Genetics Cooperative. Mult Scler 2001;7:3-11. 
88. Akesson E, Oturai A, Berg J, Fredrikson S, Andersen O, Harbo HF, et al. A genome-
wide screen for linkage in Nordic sib-pairs with multiple sclerosis. 2002;3:279-285. 
89. Coraddu F, Sawcer S, D'Alfonso S, Lai M, Hensiek A, Solla E, et al. A genome screen 
for multiple sclerosis in Sardinian multiplex families. Eur J Human Gen 2001;9:621-626. 
90. Benedikz J, Magnusson H, Guthmundsson G. Multiple sclerosis in Iceland, with 
observations on the alleged epidemic in the Faroe Islands. Ann Neurol 1994;36:175-179. 
91. Binzer M, Forsgren L, Holmgren G, Drugge U, Fredrikson S. Familial clustering of 
multiple sclerosis in a northern Swedish rural district. J Neurol Neurosurg Psy 
1994;57:497-499. 
92. Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with 
multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 
1994;44:1901-1907. 
93. Granieri E, Casetta I, Tola MR. Epidemiology of multiple sclerosis in Italy and in 
southern Europe. Acta Neurol Scand 1995;161:60-70. 
94. Koch-Henriksen N. Multiple sclerosis in Scandinavia and Finland. Acta Neurol Scand 
1995;161:55-59. 
95. Kurland LT. The evolution of multiple sclerosis epidemiology. Ann Neurol 1994;36:2-
5. 
96. Kurtzke JF. MS epidemiology world wide. One view of current status. Acta Neurol 
Scand 1995;161:23-33. 
43 
97. Kurtzke JF, Hyllested K, Heltberg A. Multiple sclerosis in the Faroe Islands: 
transmission across four epidemics. Acta Neurol Scand 1995;91:321-325. 
98. Rosati G. Descriptive epidemiology of multiple sclerosis in Europe in the 1980s: a 
critical overview. Ann Neurol 1994;36:164-174. 
99. van Ooteghem P, D Hooghe MB, Vlietinck R, Carton H. Prevalence of multiple 
sclerosis in Flanders, Belgium. Neuroepidemiology 1994;13:220-225. 
100. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurology 2003;2:117-
127. 
101. Patnaik M, Peter JB. Intrathecal synthesis of antibodies to human herpesvirus 6 early 
antigen in patients with meningitis/encephalitis. Clin Infect Dis 1995;21:715-716. 
102. Torigoe S, Koide W, Yamada M, Miyashiro E, Tanaka-Taya K, Yamanishi K. Human 
herpesvirus 7 infection associated with central nervous system manifestations. J Pediatrics 
1996;129:301-305. 
103. Nielsen L, Larsen AM, Munk M, Vestergaard BF. Human herpesvirus-6 
immunoglobulin G antibodies in patients with multiple sclerosis. Acta Neurol Scand 
1997;169:76-78. 
104. Sola P, Merelli E, Marasca R, Poggi M, Luppi M, Montorsi M, et al. Human 
herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by 
immunofluorescence analysis and of viral sequences by polymerase chain reaction. J 
Neurol Neurosurg Psy 1993;56:917-919. 
105. Wilbom F, Schmidt CA, Brinkmann V, Jendroska K, Oettle H, Siegert W. A potential 
role for human herpesvirus type 6 in nervous system disease. J Neuroimmunol 
1994;49:213-214. 
106. Soldan SS, Fogdell-Hahn A, Brennan MB, Mittleman BB, Ballerini C, Massacesi L, 
et al. Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 
44 
cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Ann 
Neurol 2001;50:486-493. 
107. The Transatlantic Multiple Sclerosis Genetics Cooperative. A meta-analysis of 
genomic screens in multiple sclerosis. Multiple Sclerosis 2001;7:3-11. 
108. Flachenecker P, Jung S, Rieckmann P, Toyka KV. sICAM-1 is not a marker for 
disease activity in the relapse-free interval of multiple sclerosis - a cross-sectional pilot 
study. J Neurol 2002;249:1001-1003. 
109. Heesen C, Schulz H, Schmidt M, Gold S, Tessmer W, Schulz KH. Endocrine and 
cytokine responses to acute psychological stress in multiple sclerosis. Brain Behav Immun 
2002;16:282-287. 
110. Barkhatova VP, Zavalishin IA, Askarova LSH, Shavratskii VKH, Demina EG. 
Changes in neurotransmitters in multiple sclerosis. Neurosci Behav Phychol 1998;28:341-
111. Cosentino M, Zaffaroni M, Marino F, Bombelli R, Ferrari M, Rasini E, et al. 
Catecholamine production and tyrosine hydroxylase expression in peripheral blood 
mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible 
relevance for activation-induced apoptosis. J Neuroimmunol 2002;133:233-240. 
112. Heesen C, Gold SM, Hartmann S, MIadek M, Reer R, Braumann KM, et al. 
Endocrine and cytokine responses to standardized physical stress in multiple sclerosis. 
Brain Behav Immun 2003;17:473-481. 
113. Lachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in 
multiple sclerosis is related to disease activity and progression of disability. Mult Scler 
2001;7:327-334. 
344 
114. de-Vera N, Cristofol RM, Rodriguez-Farre E. Protein binding and stability of 
norepinephrine in human blood plasma. Involvement of prealbumin, a 1-acid glycoprotein 
and albumin. Life Sci 1988;43:1277-1286. 
115. Feinstein DL, Heneka MT, Gavrilyuk V, Dello-Russo C, Weinberg G, Galea E. 
Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int 
2002;41:357-365. 
116. Sanders VM. The role of norepinephrine and beta-2-adrenergic receptor stimultaion in 
the modulation of Thl, Th2, and B lymphocyte function. Adv Exp Med Biol 
1998;437:269-278. 
117. Madden KS, Livnat S. Catecholamine action and immunologic reactivity. In: Ader R, 
Felten NL, Cohen N, eds. Psychoneuroimmunology. 2nd edition ed. New York: Academic 
Press Inc., 1991:283-310. 
118. Barkhatova VP, Zavalishin IA, Askarova LS, Shavratskii VK, Demina EG. 
Neurotransmitter changes in multiple sclerosis. Zh Nevr Psikh ISSK 1997;97:7-10. 
119. Berne-Fromell K, Fromell H, Lundkvist S, Lundkvist P. Is multiple sclerosis the 
equivalent of Parkinson's disease for noradrenaline? Med Hypotheses 1987;23:409-415. 
120. Chiang J, Gloff C, Yoshizawa C, Williams G. Pharmacokinetics of recombinant 
human interferon-pser in healthy volunteera and its effect on serum neopterin. Pharm Res 
1993;10:567-572. 
121. Lienert C, Andresen B, Spycher M. 2 year experience with rIFNP-lb in Switzerland. 
Mult Scler 1998;4:375 (abstract). 
46 
